Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) EMBARK Program Graduates Class of Facilitators

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its EMBARK Psychedelic-Assisted Psychotherapy Training Program have announced the graduation of highly skilled facilitators who are now prepared to handle a range of experiences that participants of psychedelic-assisted psychotherapy may undergo. The training program includes foundational training enabling participants to learn the skills necessary to provide ethical care for and work with psychedelic-assisted psychotherapy patients. EMBARK is a leading-edge model of psychedelic-assisted psychotherapy that is implemented in Cybin’s phase 1/2a trial, which is designed to evaluate CYB003, Cybin’s investigational deuterated psilocybin analog. CYB003 has potential to be a faster-acting, shorter-duration treatment for major depressive disorder (“MDD”). “There is a bottleneck of training in the field and a shortage of clinicians prepared to do this important work, and we are therefore pleased to provide high-quality training for psychedelic treatment,” said Cybin chief clinical officer Dr. Alex Belser in the press release. “It’s inspiring to see the skill, compassion and integrity these clinicians bring to their work with patients. Importantly, these highly skilled EMBARK facilitators will play a critical role in Cybin’s CYB003 Phase 1/2a trial. We congratulate the graduates on completing the EMBARK training.”

To view the full press release, visit  

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Cybin Inc. CYBN. Bookmark the permalink.

Comments are closed.